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Changes in mitochondrial genome such as mutation, deletion and depletion are common in cancer and can determine advanced
phenotype of cancer; however, detailed mechanisms have not been elucidated. We observed that loss of mitochondrial genome
reversibly induced overexpression and activation of proto-oncogenic Ras, especially K-Ras 4A, responsible for the activation of
AKT and ERK leading to advanced phenotype of prostate and breast cancer. Ras activation was induced by the overexpression
of3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), the rate-limiting enzyme ofthe mevalonate pathway. Hypoxia is known to
induce proteasomal degradation of HMGR. Well differentiated prostate and breast cancer cells with high mitochondrial DNA
content consumed a large amount of oxygen and inducedhypoxia.Loss of mitochondrial genome reduced oxygen consumption
and increased in oxygen concentration in the cells. The hypoxic-to-normoxic shift led to the overexpression of HMGR through
inhibiting proteasomal degradation. Therefore, reduction of mitochondrial genome content induced overexpression of HMGR
through hypoxic to normoxic shift and subsequently the endogenous induction of the mevalonate pathway activated Ras that
mediates advanced phenotype. Reduction of mitochondrial genome content was associated with the aggressive phenotype of
prostate cancer in vitro cell line model and tissue specimens in vivo. Our results elucidate a coherent mechanism that directly
links the mitochondrial genome with the advanced progression of the disease.
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Prostate cancer (PCa) is a signiﬁcant health problem,
representing the leading cancer diagnosis and the second
leading cause of cancer death in North American men.
1 PCa
begins as an androgen-dependent cancer that undergoes
clinical regression in response to pharmacological or surgical
strategies that reduce testosterone concentration. Despite
this treatment, the cancer frequently recurs as an androgen-
independent or castration-resistant cancer with metastatic
phenotype. Therefore, elucidation of the mechanisms
involved in the development to an aggressive metastatic
phenotype is a critical topic.
Mitochondria are essential organelles that generate ATP
through oxidative phosphorylation. This process is accom-
plished by a series of protein complexes and mitochondrial
respiratory chains encoded by nuclear DNA (nDNA) and
mitochondrial DNA (mtDNA). Human mtDNA is remarkably
small (16569bp) compared with nDNA (B10
9bp) and
encodes 13 proteins in the mitochondrial respiratory chains
(MRC), 22 transfer RNAs, and 2 ribosomal RNAs.
2
Several reports showed that mutations of mtDNA had been
identiﬁed in various types of cancer, including breast, colon,
prostate, pancreatic and other cancers.
3 The growth advan-
tageofcancercellswithspeciﬁcmutantmtDNAhasalsobeen
demonstrated in an in vivo mouse model system using cybrid
(trans-mitochondrial hybrid) cells, suggesting that speciﬁc
mutations of mtDNA give a survival advantage and
induce metastasis.
4 In PCa specimens, Chen et al.
5 reported
an extremely high incidence of somatic mutation (90%)
in the D-loop region that may cause reduction of mtDNA
content.
6
The roles of mtDNA and mitochondrial respiratory function
in biological functions has been demonstrated using mtDNA-
deﬁcient cells.
7 We previously showed that TNF and serum
starvation could not induce apoptosis in mtDNA-depleted
cells, whereas they induced apoptosis in parental cells and
cells reconstituted with normal mtDNA.
8 These results
indicate that mitochondrial respiratory function and mtDNA
are critically important in apoptosis. We showed following
observations to demonstrate the mechanisms involved in the
induction of advanced phenotype of PCa by the reduction of
mitochondrial genome content. Reduction of mtDNA content
shifted (1) androgen-dependent PCa cells to an androgen-
independent phenotype in vitro and in vivo
9 and induced (2)
epithelial-to-mesenchymal transition changes that may lead
to PCa progression,
10 (3) hypermethylation of CpG islands of
the putative tumor suppressor genes
11 and (4) abnormal
activation of NF-kB,
12 AP-1,
12 AKT,
13 ERK
10 and JNK
10 that
may lead to aggressive phenotype in PCa progression.
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www.nature.com/cddisRas-GTPases are potential candidates that can transduce
the constitutive and concurrent activation of a broad array of
effectors such as ERK and AKT. As small GTPases, Ras are
dynamically activated and inactivated with the association of
GTP or GDP, respectively. Human cancers (B25%) often
harbor (oncogenic) mutations in Ras that disable the ability
of the GTPases to dynamically be inactivated, leading to the
constitutive and concurrent activation of a diverse array of
signal pathways, for example, Raf/MEK/ERK and PI3K/Akt.
14
Although tissue studies have revealed the constitutive
and concurrent activation of ERK and Akt in the progression
of PCa, the majority of PCa tumors do not harbor RAS
mutation (oncogenes).
15 Yet, it is generally acknowledged
that the aberrant activation of Ras can shift PCa from
androgen-dependent to independent,
16 whereas the expres-
sion of dominant-negative Ras attenuates androgen-inde-
pendent phenotype,
17 indicating that Ras activation is
responsible for the phenotype of PCa. In the current study
of PCa, we investigated a pathway of metabolic and
proto-oncogenic processes including Ras activation that
aberrantly activates ERK and Akt. We denoted this as
the mitochondrial-generated progression signal (mitoGPS)
that transduces changes in mitochondrial genome in the
early-stages of PCa into the advanced progression of the
disease.
Results
Reduction of the mitochondrial genome content is
associated with PCa progression. We ﬁrst investigated
whether mitochondrial genome content changes associated
with aggressive phenotype of PCa in human tissue
specimens. Mitochondrial genomic analysis in a single cell
revealed that the mitochondrial genome copy-number/cell
was signiﬁcantly reduced in high-grade tumors (Gleason
grade 8 and 9) as compared with that in low-grade tumors
(Gleason grade 6 and 7) (Figure 1a) (Po0.01). The in vivo
observations were veriﬁed in human cell lines the early
stages androgen-dependent PCa (LNCaP), or an array of
PCa (C4-2, PC-3 and DU-145). Classical cell lines for the
in vitro evaluation of PCa, include: the castration sensitive
LNCaP established from a metastatic (supraclavicular lymph
node) lesion of human prostate adenocarcinoma;
18 the
castration resistant (CR) C4-2 isolated from recurrent
tumors that develop after castration of mice inoculated with
LNCaP;
19 and CR PCa cell lines derived from metastasis
in human bone (PC-3) and brain (DU-145).
20,21 In the current
study, mitochondrial genomic analysis showed a low
mitochondrial genome content in PC-3 and DU-145, in
addition to a signiﬁcant reduction in C4-2, relative to the
parental LNCaP (Figure 1b).
Reduction of the mitochondrial genome content
reversibly induces the aberrant activation of ERK and
Akt. We evaluated the biological impact of the reduction of
the mitochondrial genome content in the progression of PCa
by the experimental depletion of the genome from LNCaP.
We additionally utilized the MCF-7 cell line, a classical breast
cancer (BCa) established from the metastasis (pleural effusion)
of a human breast adenocarcinoma.
22 The knock-out
of the mtDNA (mtDNA-KO) from LNCaP and MCF-7 was
demonstrated in the creation of the LNr0-8 and MCFr0
cell lines, respectively.
9,10 To conﬁrm that experimental
observations that follow the loss of the mitochondrial
genome content are not of consequence to an incidental
mutation to the nuclear genome induced by ethidium bromide
treatment, the mitochondrial genome was reconstituted to
the mtDNA-KO cell lines (LNr0-8 and MCFr0) in the creation
of the mtDNA-knock in (mtDNA-KI) cells lines, denoted
as LNCyb and MCFCyb.
The mitochondrial genome contents of the indicated cell
lines were visually conﬁrmed by ﬂuorescent in situ hybridiza-
tion (FISH). Mitochondria were labeled with MitoTracker Red
and showed that presence of mitochondria in parental,
mtDNA-KO and mtDNA-KI cells (Figure 1c). Microscopic
(confocal) images also show the abundance of the mtDNA
probes localized in the mitochondria of the parental and
mtDNA-KI cells; no mtDNA probes were observed in the
mtDNA-KO cells (Figure 1c). The results were conﬁrmed by
the quantiﬁcation of the mitochondrial genome content
by QRT-PCR (Figure 1d); the mitochondrial genome
content in LNCyb and MCFCyb was partially or completely
restored, respectively, to that in LNCaP and MCF-7. We
observed that the amount of ATP in LNCaP was signiﬁ-
cantly reduced in LNr0-8 (113.3±2.0 and 73.2±2.1nM/mg
protein, respectively) (average±S.E., P-value¼0.0056) and
lactate generation was increased (1463±66 and 3416±
82nM, respectively) (average±S.E., P-value¼0.000049).
The results suggest that loss of mitochondrial genome
reduced ATP generation possibly by the reduction of
oxidative phosphorylation that might increase in anaerobic
glycolysis.
It is well documented that ERK and Akt are constitutively
activated in the progression of advanced PCa tumors.
15
Our data reveal ERK and Akt to be constitutively activated in
the mtDNA-KO of PCa and BCa, relative to the parental and
mtDNA-KI cells (Figure 1e). Of the ERKs, that is, ERK1 (p44)
and ERK2 (p42), ERK2 was the most dramatically
phosphorylated in LNr0-8 and MCFr0.
Reduction of the mitochondrial genome content in PCa
and BCa constitutively activates Ras. The interaction of
activated GTP-bound Ras with the Ras binding domain
(RBD) of Raf-1,
23 generates GTP-bound Ras–Raf
complexes that lead to the activation of ERK and Akt.
24,25
We investigated whether Ras is activated by depletion of
mitochondrial genome. No active Ras was pulled-down
from the total-protein lysates (160mg) of parental (LNCaP
and MCF-7) cells in comparison with a positive control
(Figure 2a). Meanwhile, active Ras from mtDNA-KO was
observed even when the quantity of LNr0-8 and MCFr0
lysates probed was reduced to 0.5mgo r5 mg, respectively,
active Ras was observed as two bands of intensity similar to
the positive control (Figure 2a). The experiment
demonstrates that the depletion of the mitochondrial
genome in PCa leads to the constitutive activation of Ras.
Association of the reduction of mitochondrial genome content
with the activation of Ras was veriﬁed in an array of PCa
C4-2, PC-3 and DU-145 that harbor low mitochondrial
Prostate cancer progression and mitochondrial DNA
CC Cook et al
2
Cell Death and DiseaseFigure 1 Reduction of the mitochondrial genome content in PCa and BCa reversibly induced aberrant activation of ERK and AKT. (a) Mitochondrial genome content per
cell in low (6–7) and high (8–9) Gleason grade PCa separated by laser microdissection. Student’s t-test compared PCa with a high Gleason grade (*Po0.01) (n¼8 and 6,
respectively). (b) Mitochondrial genome contents of single cells (n¼10) of an early-stage (LNCaP) PCa cell line, and an array of (C4-2, PC-3 and DU-145) PCa cell lines.
(c)FISHofthemitochondrialgenome.Green:mitochondrialgenome.Red:mitochondria.Scalebarrepresents20mm.(d)Mitochondrialgenomecontentinsinglecells(n¼8)
of the parental(LNCaP and MCF-7), mtDNA-KO(LNr0-8 and MCFr0) and mtDNA-KI(LNCyb and MCFCyb)cells. (e) Phospho-ERK, total ERK, phospho-Akt,total AKT and
b-actin in total-protein lysates (30mg) of the indicated cell lines
Figure2 ReductionofthemitochondrialgenomecontentinPCaandBCaconstitutivelyactivatesRas.(a)Activated(GTP-bound)Raswaspulleddownanddeterminedby
western blotting. Negative controls (*GDP) and positive controls (**GTPgS): before pull-down, an aliquot of total protein lysate was pre-loaded with GDP or GTPgS,
respectively. (b) Activated Ras in total-protein lysates (160mg) of the indicated PCa cells lines. (c) DAB2IP in total-protein lysates (90mg) of normal PrEC and the indicated
PCa cell lines
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Cell Death and Diseasegenome contents, relative to the early stages of PCa LNCaP
(Figures 1b and 2b).
Theshiftofnormalepithelialcellstotheearly-stagesofPCa
and BCa is associated with the genetic silencing of RasGAPs,
particularly the DOC-2/DAB2 interactive protein (DAB2IP).
26
Theattenuation of DAB2IP activity inPCa diminishes the cells
ability to amplify the GTPase activity of Ras, leading to
the prolonged accumulation of active GTP-bound Ras.
27 We
observed the expression of DAB2IP to be expressed in the
prostate epithelial cells (PrEC), but not in all PCa including
LNCaP, C4-2, DU-145 and PC-3 (Figure 2c). Collectively the
experiments demonstrate that the shift of normal prostate
epithelial cells to PCa is associated with a silencing of a
RasGAPthatisnotenoughtoexplainwhyRasisnotactivated
in early stages of PCa LNCaP.
Reduction of the mitochondrial genome content in PCa
overexpresses proto-oncogenic K-Ras 4A. The human
cell contains three nuclear-encoded RAS genes that encode
four isoforms of Ras: H-Ras, N-Ras and two splice variations
of K-Ras, K-Ras 4A and K-Ras 4B. We observed the
protein level of K-Ras 4A to be greatly elevated in the
mtDNA-KO (LNr0-8 and MCFr0), relative to the parental
cells. Reconstitution of the mitochondrial genome to the
mtDNA-KO attenuated the aberrant K-Ras 4A expression
(Figure 3a). Expression level of K-Ras 4A in mtDNA-KO cells
was exceptionally high as compared with that of K-Ras 4B,
H-Ras and N-Ras. A similar expression pattern was
observed for the transcript levels of K-Ras 4A (Figure 3b).
Association of the reduction of mitochondrial genome content
with increased expression of K-Ras 4A was veriﬁed in an
array of PCa C4-2, PC-3 and DU-145 that harbor low
mitochondrial genome contents, relative to the early stages
of PCa LNCaP (Figures 1b and 3c).
We note that the constitutive activation of Ras
observed with the depletion of the mitochondrial genome
was not a consequence of oncogenic mutation in
nucleotide sequences that encode for codons 12, 13 or 61
ofK-Ras.
28Inasubsequentexperimentwedemonstratedthat
silencing of K-RAS in LNr0-8, by transfection of K-RAS
siRNA, reduced the expression of K-Ras 4A and the
phosphorylation of ERK and Akt, but not total ERK nor total
AKT (Figure 3d). Collectively, the experiments demonstrate
that the reduction of the mitochondrial genome leads to
the aberrant expression and activation of Ras, predomi-
nantly proto-oncogenic K-Ras 4A, and a process that is
reversible with the reconstitution of the mitochondrial
genome.
Figure 3 Reduction of the mitochondrial genome content in PCa overexpresses proto-oncogenic K-Ras 4A. (a) Ras isoforms in total protein lysates (30mg) of the
indicated cell lines. Exposure time was 10s, excluding K-Ras 4A (0.5s). (b) RT-PCR analysis of Ras (cDNA) transcripts in total-cDNA constructed from total-RNA lysates of
the indicated cell lines. (c) K-Ras 4A in total-protein lysates (30mg) of the indicated cell lines. (d) Phospho-ERK and phospho-Akt in total-protein lysates (30mg) of LNr0-8
transfected in the absence (control) or presence of K-RAS siRNA or non-speciﬁc siRNA. Protein levels of K-Ras 4A were evaluated in *(0.5mg) total-protein lysates
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Cell Death and DiseaseHMGR (3-hydroxy-3-methyl-glutaryl-CoA reductase)
expression is responsible for the aberrant activation of
Ras mediated by the reduction of the mitochondrial
genome content. Ras must translocate to cellular
membrane by post-translational modiﬁcations that enable
the (GTP-bound) Ras–Raf complexes to activate effectors at
cellular membranes.
29 Localization of Ras to the cellular
membrane is mediated by the prenylation of Ras, that is, the
addition of farnesyl to the ﬁrst cysteine (CAAX) of the
C-terminus.
30 Farnesyl moieties for the prenylation of Ras
are derived from farnesyl pyrophosphate, an intermediate of
the mevalonate pathway that is catalytically transferred by
farnesyltransferase (FTase).
31
Immunohistochemical analysis conﬁrmed that expression
of Ras was greatly increased in LNr0-8 as compared
with LNCaP (Figure 4a). Figures 4a and b also demonstrates
that Ras located only in cytosolic fraction in LNCaP
and cellular membrane and certain organelle in LNr0-8
suggesting that the depletion of the mitochondrial genome
signals the localization of Ras to the cellular membrane
and speciﬁc organelle. Farnesylation of Ras can be
repressed with lovastatin-mediated inhibition of the rate-
limiting step of the mevalonate pathway – the metabolism
of HMG-CoA to mevalonate by HMGR.
32 Addition of
lovastatin to the culture of LNr0-8 generated the cytosolic
accumulation of Ras, in addition to a shift to LNCaP-like cell
morphology, both of which were reversed with co-application
of exogenous mevalonate (Figure 4b). To directly inhibit
the farnesylation of Ras, farnesyltransferase inhibitors
(FTIs) have been designed as peptidomimetics of the
C-terminus (CAAX) of Ras.
32 The supplementation of
lovastatin or FTI-276 diminished the phosphorylation of
ERK and Akt in LNr0-8 (Figures 4c and d). The results
suggest that the endogenous activity of the mevalonate
pathway is necessary for the constitutive activation of
Ras in LNr0-8.
Figure 4 The endogenous mevalonate pathway mediates the maturation of aberrant Ras signals in PCa devoid of the mitochondrial genome. (a) Confocal images
(z-slices) of anti-total-Ras (Alexa-488 labeled-anti-mouse IgG) within an intracellular plane of formaldehyde ﬁxed cultures of the indicated cell lines. Matched image sets were
mapped to a common linear gray-scale range (*overexposed image of LNCaP). Scale bars represent 20mm. (b) Confocal images (z-slices) of anti-total-Ras in mtDNA-KO
(LNr0-8) cells cultured 12h in the absence (control) or presence of lovastatin (5mM) with or without mevalonate (1mM). (c and d) Phospho-ERK, total ERK, phospho-Akt,
total AKT and b-actin in total-protein lysates (30mg) of LNr0-8 cells cultured 24h in the absence (control) or presence of lovastatin (c), or (d) 48h in the absence (control) or
presenceofFTI-276.(e)HMGRintotal-proteinlysates(30mg)oftheparental,mtDNA-KOandmtDNA-KIofLNCaP.(f)HMGRintotal-proteinlysates(30mg)ofindicatedcells
as assessed by western blot with anti-HMGR
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Cell Death and DiseaseThen, we further investigated the potential cause for
upregulation of mevalonate pathway. We observed an
elevation of the expression of HMGR with the depletion of
the mitochondrial genome (LNr0-8) could be attenuated with
thereconstitutionofthegenome(LNCyb)(Figure4e).Wealso
observed the expression of HMGR was enhanced associated
withthereductionofthemitochondrialgenomecontentinPCa
celllines(Figure4f).Theseresultsindicatethatanelevationin
the endogenous expression of HMGR is responsible for the
activation of Ras when the mitochondrial genome content is
reduced.
Inhibition of mitochondrial respiration is responsible for
HMGR expression possibly through the inhibition of
proteasomal degradation. Mitochondrial genome encodes
13 proteins in MRC and therefore reduction of mitochondrial
genome leads to the inhibition of mitochondrial respiration.
To determine if the induction of HMGR expression is induced
by the inhibition of mitochondrial respiration, LNCaP
cells were cultured in the absence or presence of inhibitors
of various complexes of the MRC: rotenone inhibits
complex I; antimycin A inhibits complex III; oligomycin
inhibits Fo-ATPase of complex V. Rotenone, antimycin A
and oligomycin at the concentration used inhibited the
oxygen consumption rate of LNCaP (32.6%, 35.2% and
34.4%, respectively) and enhanced the expression of HMGR
(Figure 5a).
HMGR is regulated by multiple feedback mechanisms,
including: transcriptional and/or translational regulation,
PTMs, and/or proteasomal degradation by both sterol
and non-sterol products of the mevalonate pathway.
33 We
investigated whether proteasomal degradation is associated
with high expression of HMGR. Incubation with proteasomal
inhibitor N-[N-(N-Acetyl-L-leucyl)-L-leucyl]-L-norleucine
(ALLN) in LNCaP increased the protein level of HMGR
(Figure 5b), suggesting that early stage PCa maintain low
expression level of HMGR by proteasomal degradation.
HMGR expression in PCa is enhanced by the hypoxic-
to-normoxic shift. A recent study has demonstrated that
hypoxia induces the proteasomal degradation of HMGR.
34,35
As expected, oxygen consumption is well associated with the
content of mitochondrial genome in PCa cell lines (Figures
1b and 6a). From this observation, we hypothesized that
LNCaP cells induce hypoxia by high consumption rate of
oxygen leading to hypoxia-induced HMGR degradation, and
that in advanced PCa the hypoxic state is retarded with
the inhibition of respiration, that is, by the reduction of
mitochondrial genome content, leading to the accumulation
of HMGR expression. Interestingly, the oxygen concentration
of surrounding cells was greatly reduced with the culture
of LNCaP and MCF-7, as observed with the induction of
hypoxia (12.3 and 4.2mM, respectively) in an hour (Figures
6b and c, respectively). The hypoxia-inducing activity of the
parental cells was greatly reduced with the depletion of the
mitochondrial genome, and recovered with the reconstitution
of the genome (Figures 6b and c). To investigate whether the
hypoxic-to-normoxic shift induced by the reduction of
mitochondrial genome content augments the expression of
HMGR, the oxygen condition in the culture of LNCaP cells
was increased (30%, 310mM) to establish an increased
intracellular oxygen condition. The expression of HMGR and
the phosphorylation of ERK were ampliﬁed within 6h of
culture in the enriched oxygen condition (Figure 6d). The
study was further reﬁned by the culture of LNr0-8 in low
oxygen environments to exogenously induce a normoxic-to-
hypoxic shift in LNr0-8. The greatly reduced-oxygen
condition (0.2%, 2.1mM), but not 1, 5 or 20%, attenuated
the expression of HMGR and the phosphorylation of ERK
(Figure 6e), within 6h of culture in the 0.2% oxygen
environments (Figure 6f). The data indicate that hypoxic-to-
normoxic or normoxic-to-hypoxic shifts regulate the protein
levels of the HMGR enzyme. We observed the hypoxia-
inducing activity of advanced PCa cell lines to be low
(Figure 6g), an observation that correlates with the oxygen
consumption (Figure 6a) and the dysregulation/reduction of
the steady state of the mitochondrial genome content in the
progression of PCa (Figure 1b).
Endogenous or exogenous induction of the mevalonate
pathway in PCa signals the progression of the advanced
phenotype in vitro and in vivo. To verify that exogenous
androgens amplify the viability of the early-stages PCa,
LNCaP were cultured in androgen-deprived media without
(Figure 7a) or with synthetic androgen (R1881) (Figure 7b).
Meanwhile, the androgen-deprived media was supplemented
with exogenous mevalonate to induce the mevalonate
pathway in the absence or presence of exogenous
androgen (Figures 7c and d, respectively). Figure 7e
demonstrates that exogenous androgens amplify the
growth and proliferation of LNCaP in a dose-dependent
fashion that is diminished in the presence of exogenous
mevalonate. Alternatively, mevalonate alone supports growth
in the absence of exogenous androgen (Figures 7c and e).
The experiment reveals that exogenous mevalonate induces
androgen independence.
In subsequent experiments we evaluated the essentialness
of the endogenous mevalonate pathway on the viability of
Figure 5 Inhibitors of mitochondrial respiratory chain and proteasomal
degradation enhanced expression of HMGR. (a) HMGR expression and ERK
phosphorylation were evaluated in total-protein-lysates (30mg) of LNCaP cultured
6h in the presence or absence of rotenone (400nM), antimycin A (160ng/ml) and
oligomycin(8mg/ml). (b) HMGR in total-protein lysates of LNCaP cultured 6h in the
absence (control) or presence of ALLN at the indicated dosages
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Cell Death and DiseasePCa that harbor or are devoid of the mitochondrial genome.
The viability of LNr0-8 was signiﬁcantly diminished in the
presence of lovastatin, relative to the parental and mtDNA-KI
cells (Figure 7f); the lovastatin-mediated inhibition of the
viability of the mtDNA-KO was prevented by mevalonate
(Figure 7g). The experiments demonstrate that a reduction of
the mitochondrial genome content in PCa is transduced into
the advanced phenotype via an endogenous induction of the
mevalonate pathway.
LNCaP cells are known to gradually acquire more aggres-
sive growth within in vitro and in vivo environments.
36,37 In
order to investigate, in vivo, the role of mevalonate pathway in
the shift of LNCaP to more aggressive growth phenotype, we
inoculated LNCaP cells into athymic nude mice. Following the
developmentoftumorswithdiametersof9–10mm,micewere
randomly assigned to four experimental groups as follows;
(1) control, (2) lovastatin, (3) mevalonate and (4) lovastatin
and mevalonate. The mean tumor volume for each group was
quantiﬁed on Day 0 (pre-treatment): 377±105, 336±106,
454±86 and 383±44 (average±S.D. mm
3). Subsequently,
pumps were utilized to systemically deliver either mevalonate
(group 3 and group 4) or isotonic saline (group 1 and group 2)
into mice, whereas lovastatin was consumed in the diet of
mice of group 2 and group 4. Figure 8a demonstrates that
the progressive growth of LNCaP (group 1) in mice was
signiﬁcantlyreducedwiththetreatmentoflovastatin(group2);
the growth inhibitory effect of lovastatin was reversed with
exogenous mevalonate (group 4). Meanwhile, the adminis-
tration of exogenous mevalonate alone (group 3) slightly but
signiﬁcantly enhanced the growth of LNCaP. These results
indicate that the mevalonate pathway isresponsible for in vivo
advanced growth in the xerographic model of PCa.
Discussion
Our collective report demonstrates in PCa that the (1)
inhibition of respiration, by reduction of the mitochondrial
genome content, shifts cells from a hypoxic-to-normoxic state
(2) that attenuates the endogenous proteasomal degradation
oftheHMGRenzyme;(3)theincreaseinmevalonatepathway
(4) induces the constitutive activation of nuclear-encoded
proto-oncogenic Ras (5) that signal for an array of cancer
progression signals (Figure 8b). We denote the coherent
series of events as the mitoGPS.
Figure 6 HMGR expression in PCa is enhanced by the hypoxic-to-normoxic change. (a) Oxygen consumption rates of the indicated cell lines (1 10
6cells/ml)
(mean±S.E.) (n¼3). (b and c) Oxygen concentration surrounding the indicated cell lines (2 10
6cells/ml) (mean±S.E.) (n¼3). (d) HMGR and phospho-ERK in total-
protein-lysates (30mg) of LNCaP cultured in 30% oxygen for the indicated time periods. LNCaP were cultured in 20% oxygen as a control. (e) HMGR and phospho-ERK in
total-protein-lysates(30mg)ofLNr0-8seeded(1 10
6cells/ml)overnight,thencultured6hintheindicatedoxygenconcentration,or(f)in0.2%oxygenfortheindicatedtime
periods. LNr0-8 cells were cultured in 20% oxygen as a control. (g) Oxygen concentration surrounding the indicated cell lines (2 10
6 or 1 10
6cells/ml) (mean±S.E.)
(n¼3) after 2h incubation
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Cell Death and DiseaseThe pathological condition of a deprivation in an adequate
oxygen supply to the body is referred to as hypoxia, a
condition that is transduced at the molecular level into
hypoxia-related signals that allow a cell(s) to adjust to the
extracellular environment. We are the ﬁrst to directly establish
the mitochondrion as a direct physiological source of hypoxia
in an in vitro system. Our results demonstrate that the
reduction of the mitochondrial genome content diminishes the
hypoxic state of the early stages of PCa and BCa, generating
a hypoxic-to-hyperoxic shift in the oxygen content that
is transduced into the overexpression of HMGR; subse-
quently, the induction of the mevalonate pathway activates
proto-oncogenic Ras that signals the constitutive and con-
current activation of a diverse array of cancer progression
Figure7 EndogenousorexogenousinductionofthemevalonatepathwayinPCasignalstheprogressionofthephenotype.MicroscopicimagesofLNCaPcultured7days
in androgen-deprived media with 5% charcoalstripped bovineserum (no androgen)(a) supplementedwith syntheticandrogen R1881(b), mevalonate (c), or mevalonateand
R1881 (d). Scale bar represents 100mm. (e) Total cell viability was quantiﬁed by a calcein assay (arbitrary unit (A.U.)±S.E.) (n¼3). Student’s t-test compared the control
group in the absence or presence of R1881 (*Po0.01, except for 10pM and 100pM, Po0.05), and the control and mevalonate groups cultured in the absence of R1881
(**Po0.01). (f) Viability of the parental, mtDNA-KO and mtDNA-KI of LNCaP cultured 4 days in the absence or presence of lovastatin (n¼3). Student’s t-test compared
LNCaP and LNr0-8 cultured in the same lovastatin concentration (*Po0.01). (g) Addition of mevalonate to the lovastatin-mediated inhibition of the viability of LNr0-8.
Total cell viability was quantiﬁed by a crystal violet assay (average AD590±S.E.) (n¼3). Student’s t-test compared the lovastatin groups with the control (no lovastatin,
no mevalonate) (*Po0.001)
Figure8 TheeffectoflovastatinandmevalonateontumorformationsofLNCaPinathymicnudemice.AthymicBALB/c(nu/nu)miceweresubcutaneouslyinoculatedwith
LNCaP. The effect of lovastatin and mevalonate on tumor growth was investigated as described in Materials and Methods. The tumor volumes were measured weekly and
calculated. The relative tumor volume was calculated as percent of control±S.D. by assuming the rate of each tumor volume on day 0 to be 100% (n¼6). Student’s t-test
compared the control and lovastatin group showed signiﬁcance at day 14, 21 and 28 days (*Po0.01), and the control and mevalonate groups at day 14 and 21 (**Po0.01)
and 28 days (***Po0.02)
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Cell Death and Diseasepathways that advance the disease. Reports indicate that
hypoxia inhibits lanosterol demethylase, an oxygen requiring
enzyme, and accumulates lanosterol (molecules in cholester-
ol pathway) and that accumulation of lanosterol induces Insig-
mediateddegradationofHMGR.HypoxiaalsoactivatesHIF-1
to induce expression of insig.
34,35 Whether this pathway is
activated in our system is now under investigation. The roles
of ROS may not be likely as mtDNA-deﬁcient cells generate
reduced superoxide.
38
With primary PCa composed of a mixture of cells with high
or low mitochondrial genome content,
39 cells with high
mitochondrial content may generate more hypoxia-induced
changes that beneﬁt the growth and maintenance of both
groups under high cell density conditions, that is, the primary
tumor site. In contrast, we speculate in the initiation of
metastasis that the progressive induction of hyperoxia with
the reduction of cell-density further enhances the mitoGPS,
advancing the phenotype of cancer that harbor a reduced
copy-number of the mitochondrial genome. It is plausible that
the mitoGPS is a ubiquitous (patho)physiological response to
the etiology and/or progression of a broad spectrum of human
diseases that are attributed to respiratory incompetent
mitochondria in various degenerative diseases (e.g., meta-
bolic syndrome and diabetes). For example, as K-Ras 4A is
responsible for aldosterone signaling,
40 the roles of mtDNA
changes on hypertension is implicated.
In conclusion, our report has identiﬁed an intricate interac-
tion of prospective (mitochondrial and nuclear encoded)
markers for the selective penetrance, progression and prog-
nosis of PCa, and potentially a diverse array of respiratory-
deﬁcient (e.g., aging) pathologies.
Materials and Methods
Materials. Uridine, sodium pyruvate, rotenone, antimycin A, oligomycin A,
mevalonate and FTase-276 were purchased from Sigma-Aldrich (St. Louis, MO,
USA).;Lovastatin from A.G. Scientiﬁc (San Diego, CA, USA) and ALLN from Fisher
Scientiﬁc (Pittsburgh, PA, USA).
Cell culture. LNCaP and C4-2 were purchased from UROCOR (Minnetonka,
MN, USA); MCF-7, PC-3 and DU-145 were purchased from ATCC (Manassas, VA,
USA); and, PrEC was purchased from Lonza (Allendale, NJ, USA). PC-3, DU-145,
LNCyb, MCF-7 and MCFCyb were cultured in Dulbecco’s modiﬁed Eagle medium
with a high level of D-glucose (4.5g/l) and sodium pyruvate (110mg/l) (Invitrogen,
Allendale, NJ, USA), additionally supplemented with 5% fetal calf serum (FCS,
ThermoScientiﬁc,Barrington, IL, USA).PrECwas culturedin prostateepithelialcell
basalmedia (PrEBM,Lonza) supplementedwith PrEGMSingleQuots:BPE,insulin,
HC, GA-1000, retinoic acid, transferrin, T3, epinephrine and rhEGF (no. CC-4177,
Lonza). Media for LNr0-8 and MCFr0 was additionally supplemented with uridine
(50mg/ml) and sodium pyruvate (100mg/ml). Media for BCa cells was additionally
supplemented with bovine insulin (0.01mg/ml) (Sigma-Aldrich).
Microdissection. Samplesandmatched clinicalinformation were obtainedfrom
the Division of Urology at McClellan’s Memorial Veteran’s Hospital (Little Rock, AR,
USA). All patient-derived biological specimens were collected and archived under
protocols approved by the Human Subjects Committee of the University of Arkansas
for Medical Science Institutional Review Board (UAMS IRB no. 55578). In all,14 PCa
patientsparticipatedinthestudy(agerangingfrom49–73years;average61.7years).
According to the clinical information available, none of these individuals had any
medical condition or had any treatment known to affect the prostate. In all, 14 PCa
tissues were collected by radical prostatectomy specimens. The cancers ranged from
Gleason grade 3 þ 3, 3 þ 4, 4 þ 3, 4 þ 4, 4 þ 5o r5þ 4. Fresh specimens
werefrozen at  801Candsectionedbycryostatto yield8mmsections. Each section
wasﬁxedinmethanolandstainedinMayer’shematoxylin.Beforemicrodissection,cut
sections were dehydrated in ethanol. An expert pathologist selected cancer and
normal epithelial regions, and then individual cells were collected by laser
microdissection using the Leica AS LMD system (Leica Microsystems, Richmond,
IL, USA). The dissected cells were transferred by gravity alone into a microcentrifuge
tube placed directly underneath the tissue section. The tube was ﬁlled with digestion
buffer (20ml) containing SDS (0.0015%), proteinase K (0.2mg/ml) and EDTA
(4.5mM) to ensure the isolation of DNA. After incubation (551C for 3h), the samples
were boiled (951C for 10min) to inactivate proteinase K.
FISH of mitochondrial genome. Alexa-488 dye labeled mtDNA-probes
(B600bp) were created from six overlapping PCR products (B3.3kb in length)
that collectively represent the entire human mitochondrial genome were prepared.
An equal amount of PCR product from each reaction were combined, and the
pooled products were nick-translated and labeled with the Alexa-488 dye as
instructed in the ARES Alexa-488 DNA Labeling Kit (Invitrogen).
Cells wereseeded(60%conﬂuence)on submergedcoverslips.Tocounterstain
the mitochondria, cell cultures were incubated (20min at 371C) in MitoTracker Red
dye(300nM)(MolecularProbes).CellswerethenwashedinPBS,andﬁxed(10min
at 371C) in 4% formaldehyde (Ted Pella, Redding, CA, USA). Fixed cells were
washed in PBS, and permeabilized (5min at 251C) in 0.1% Triton X-100 (Sigma-
Aldrich). Cells were then washed in PBS, and treated (90min at 371C) with 0.1mg/
ml DNase-free RNase (Roche Diagnostics, Indianapolis, IN, USA). Cells were then
washed with PBS; meanwhile, the mtDNA probes (0.5ng/ml) were denatured
(10min at741C)informamide(50%),dextransulfate(10%)and2  salinesodium
citrate (SSC) buffer. Cover slips were mounted with denatured probes (15ml) onto
pre-warmed slides (741C). Cover slips and the mtDNA probes were sealed to the
slides with rubber cement and left overnight in a dark humidiﬁed chamber(371C) to
hybridize. After hybridization the cover slips were removed from the slides and
washedin2  SSCbufferat251C,followedbysequentialwashesin2  SSCand
0.5  SSC buffer at 401C. Cover slips were then rinsed in PBS and mounted to
slides by ProLong antifade reagent with or without 40, 6-diamidino-2-phenylindole
dihydrochloride (DAPI) (Invitrogen).
Wide ﬁeld ﬂuorescence microscopy. Wide ﬁeld microscopy imaging
was performed with a Zeiss Axioskop 40 microscope (Carl Zeiss, Thornwood, NY,
USA) ﬁtted with a  40/0.75 NA objective. Images were captured with a Zeiss
AxioCam MRm camera, and collected using AXIOVISION software (Carl Zeiss).
Matched image sets were mapped to a common linear gray-scale range. Images
were prepared for publication with ADOBE PHOTOSHOP software (Adobe
Systems, San Jose, CA, USA).
Spinning disk ﬂuorescence microscopy. Confocal imaging was
performed with a Zeiss Axiovert 200M microscope (Carl Zeiss) ﬁtted with a
 100/1.40 NA objective and a CARV II spinning disk confocal accessory (BD
Bioimaging, RockVille, MA, USA) mounted to the sideport of the microscope.
Images were captured with a Retiga EXi camera (Qlmaging, Surey, BC, Canada).
The microscope was operated in multitrack conﬁguration with alternative excitation,
as controlled with IVISION MAC (BioVision Technologies, Exton, PA, USA). Image
stacks were collected through the entire cell depth, and then compressed into a
single plane using maximum intensity projection and IVISION (Atlanta, GA, USA)
software.Whennoted,asinglez-slice(plane)wascapturedusinga  100/1.40NA
objective. Matched image sets were mapped to a common linear gray-scale range.
Images were prepared for publication with ADOBE PHOTOSHOP software (Adobe
Systems).
SDS-PAGE and western blotting. Cells were lysed in radioimmuno-
precipitation assay buffer supplemented with DTT (0.5mM), and protease and
phosphatase inhibitors (100  Halt protease and phosphate inhibitor cocktail, no.
1861281, Thermo Scientiﬁc). Cytosolic extracts were isolated by centrifugation
(12000g for 15min at 41C), and the protein concentration was determined by a
protein assay (Bio-Rad Protein Assay, Bio-Rad, Hercules, CA, USA). Total-protein
lysates were suspended in reducing SDS gel-loading buffer, denatured (951C for
5min) and subjected to electrophorectic separation in polyacrylamide slab gels in
the presence of SDS (i.e., SDS-PAGE), and then transferred to immobilon-P
membrane (Millipore, Bellelica, MA, USA). After a wash in Tris Buffered Solution
(TBS), the membrane was incubated overnight (41C) in primary antibody diluted
(1:1000) in bovine serum albumin (5% BSA, Sigma-Aldrich). Antibodies utilized in
the current study are as follows: rabbit anti-phospho ERK(T202/Y204) (no. 9101),
rabbit anti-total ERK (no. 9102), rabbit anti-phospho Akt(Ser473) (no. 9271), rabbit
anti-totalAkt(no.9272),rabbitanti-b-actin(no.4967,CellSignaling,Beverly,MA,USA),
Prostate cancer progression and mitochondrial DNA
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Cell Death and Diseasemouse anti-total Ras (clone RAS10, no. 05-516, Millipore), rabbit anti-H-Ras (C-20,
no. sc-520), rabbit anti-K-Ras 4A (C-17, no. sc-522), rabbit anti-K-Ras 4B
(C-19, no. sc-521), rabbit anti-N-Ras (C-20, no. sc-519, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit anti-total DAB2IP (no. A302-439A, Bethyl
Laboratories, Montgomery, TX, USA), rabbit anti-HMGR reductase (no. 07-457,
Millipore), and mouse anti-GAPDH (no. MAB374, Millipore). The membrane was
then washed in TBS, and incubated (1h at RT) with HRP-linked anti-mouse IgG or
anti-rabbit IgG diluted (1:10000) in 5% BSA-TBS (no. 7074 and no. 7076,
respectively, Cell Signaling). The membrane was then washed in TBS, and
analyzed with ECL Plus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) by
autoradiography ﬁlm.
Rasactivation(PullDown)assay. Activated(GTP-bound)Raswaspulled
down from total-protein lysates of cell cultures by a Ras Activation Assay kit (Kit no.
17-218, Millipore). Brieﬂy, an agarose-bound GST fusion protein corresponding to
the RBD (residues 1–149) of human c-Raf was utilized to bind and precipitate
GTP-bound Ras from total-protein lysates. As a negative control, before pull-down
an aliquot of total protein lysate was pre-loaded with GDP to deactivate
(GTP-bound) Ras to the GDP-bound state. As a positive control, before pull-
down an aliquot of total protein lysate was pre-loaded with nonhydrolyzable GTPgS
to active (GDP-bound) Ras to the GTP-bound state. Protein levels of pulled down
Ras in samples were analyzed by SDS-PAGE and western blot.
GenomicsequencingofK-RAS. ADNAextractionkit(ZRGenomicDNAII
Kit, Zymo Research, Irvine, CA, USA) was used to prepare genomic DNA. Primers
were custom synthesized (Integrated DNA Technologies, Coralville, IA, USA) to
amplify the K-RAS gene in exon 1 (codon 12 and 163bp) and in exon 2 (codon 61,
133bp): exon 1: exon 1 (sense 50-GGCCTGCTGAAAATGACTGAA-30 and anti-
sense 50-GGTCCTGCACCAGTAATATGC-30) and exon 2 (sense 50-CAGGATTCC
TACAGGAAGCAAGTA-30 and anti-sense 50-CACAAAGAAAGCCCTCCCCA-30).
PCR was carried out with La Taq DNA polymerase (TaKaRa, Shiga, Japan): 941C
for1min;30 sequentialcycles of941C for15s, 551C (exon1)or 601C(exon2) for
30s, and 721C for 10s; with a ﬁnal elongation at 721C for 1min. PCR products
were loaded onto an agarose gel (2%) to conﬁrm a single target band. The target
band was cut out and puriﬁed using the Wizard PCR Preps DNA Puriﬁcation
System (Promega, Madison, WI, USA), then subjected to direct sequencing with
a 3100 Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA; UAMS DNA
Sequencing Core Facility, Little Rock, AR, USA).
Measurementofoxygenconsumption. Cells(1 10
6)weresuspended
in 1ml of culture medium pre-equilibrated to 20% oxygen and then placed in a
sealed respiration chamber equipped with a thermostat control and a micro-stirring
device (Oxytherm, Hansatech Instrument, King’s Lynn, Norfolk, UK). The oxygen
contents in the starting medium were normalized assuming an O2 concentration of
217mM in air-saturated medium at 371C( n¼3).
Oxygen concentration measurements by OxoPlate. The OxoPlate
OP96U (PreSens) contains oxygen-sensitive, polystyrene particles PSLi-Pt-1
(Opto-Sense). Sulforhodamin is covalently attached to these particles as reference
dye, and a platinum porphin is incorporated as indicator dye. The sensor has a
thickness of about 10mm and is ﬁxed at the bottom of each well of a 96-round
bottom microtiter plate (Greiner, Monroe, NC, USA). Cells (200ml) were added to
each well at the indicated cell density. Wells containing oxygen-free water (cal 0)
and air-saturated water (cal 100) served as standards. Oxygen-free water was
prepared by dissolving sodium sulﬁte (1%) in water; in the wells, the oxygen-free
water was overlaid with mineral oil (50ml) to prevent the diffusion of oxygen into the
wells.Theoxygenconcentration(ﬂuorescence)ineachwellwasquantiﬁedfor3hin
5-min intervals, as measured in a dual kinetic mode (Synergy HT, BIO-TEK,
Einooski, VT, USA): ﬁlter pair 1 (544/650nm) detects ﬂuorescence of the indicator
dye; the second measures ﬂuorescence (544/590nm) of the reference dye (n¼3).
Calculation of oxygen concentration. The relationship between
ﬂuorescence and dissolved oxygen is nonlinear, as described by the
Stern–Volmer equation:
IR
IR;0
¼
1
1 þ Ksv½O2 
where, IR,0 is the ﬂuorescence intensity ratio in the absence of oxygen; IR is
the ﬂuorescence intensity ratio at the oxygen concentration [O2], and KSV the
Stern–Volmerparameter.IntensityratiosIRarecalculatedforeachindividualwellby
dividingtheintensityoftheindicatordyebytheintensityofthereferencedye.Atwo-
point calibration is sufﬁcient: [O2]¼0 and at [O2]¼[O2]*, where [O2]* is the
saturation concentration.
Oxygen concentration as a percentage of air saturation was calculated for each
well, as follows:
pO2 ¼ 100 
KO
IR
  1

=
KO
K100
  1

where the constant K0 is deﬁned as IR of well ﬁlled with cal 0. Analogously, K100 is
deﬁned as IR of well ﬁlled with cal 100.
Culture of cells in high or low oxygen condition. LNCaP (0.25 10
6
cells) and LNr0-8 (1 10
6 cells) were seeded in a 6-cm culture dish overnight in a
humidiﬁed atmosphere of 5% CO2 in an incubator. Increased and reduced oxygen
incubations were carried out in a C-chamber (no. C-174, BioSpherix, Lacona, NY,
USA), regulated by a PRO-OX 110 oxygen controller (Biospherix) to establish the
indicated oxygen concentrations. (DMEM þ5% FCS, 50mM HEPES) and
Additional Gases (nexAir: Nitrogen Liquid Medical Grade LS180ltrs 22psi (no. LQ
NI-NF-LS180) (Santa Cruiz, CA) and Oxygen Medical Grade 200þcft (no. HP
OX-USP-2)).
QRT-PCR of the mitochondrial genome content. The mitochondrial
genome content of individual cells was quantiﬁed by QRT-PCR as previously
described.
39
RT-PCRofRAS. Total-RNAwasisolatedwithaQiagenRNA-PlusMiniEasykit
(no. 74134, Qiagen , Valencia, CA, USA), subjected (2mg) to a gDNA eliminator
spin column, primed with oligo (dT)18 20 (Invitrogen), and reverse transcribed by
SupersciptIIIReverseTranscriptase(Invitrogen).Primerswerecustomsynthesized
(Integrated DNA Technologies) to amplify the cDNA for H-RAS (111bp), K-RAS 4A
(560bp), K-RAS 4B (711bp), N-RAS (682bp), HMGR (280bp) and GAPDH
(89bp): H-RAS (sense 50-ATGACGGAATATAAGCTGGT-30 and anti-sense 50-
CTCTATAGTGGGGTC GTATT-30); K-RAS 4A (sense 50-GAGAGAGGCC
TGCTGAAAATG-30 and anti-sense 50-ACACAGCCAGGAGTCTTTTCTTC-30);
K-RAS 4B (sense 50-AGCGCGGCGCAGGCACTGAA-30 and anti-sense
50-TTAGTGTAATGTACAAAAATTACCA-30); N-RAS (sense 50-CTGTGGTCCTA
AATCT;GTCC-30 and anti-sense 50-CAGTGCAGCTTGAAAGTG -30); HMGR
(sense50-TGCTGCTTTGGCTGTATGTC-30 andanti-sense 50-TGAGCGTGAACAA
GAACCAG-30); GAPDH (sense 50-GGTGGTCTCCTCTGACTTCAA-30 and anti-
sense 50-AGCTTGACAAAAGTGGTCGTTG-30). The entire coding sequence of
GAPDH cDNA was ampliﬁed as a control. Ex Taq (TaKaRa) was used for the
ampliﬁcation of Ras cDNA or HMGR cDNA from total-cDNA, 50ng or 200ng,
respectively. The PCR cycle to amplify target cDNA is as follows: 941C for 1min,
followed by 20 (Ras) or 35 (HMGR/GAPDH) sequential cycles of 941C for 15s, the
denoted annealing temperature (as follows) for 1min, and 721C for 1min; with a
ﬁnal elongation at 721C for 5min. Annealing temperatures for primers: H-RAS
(561C); K-RAS 4A (501C); K-RAS 4B (561C); N-Ras (581C); HMGR (581C);
GAPDH(581C).PCRproductswereseparatedinagarosegels(RAScDNA,except
H-RAS 1.2%; HMGR 1.5%; H-RAS and GAPDH 2%) supplemented with ethidium
bromide (1:20000), and then visualized by a UV transilluminator (UVP, Upland,
CA, USA).
K-RAS siRNA. Stealth siRNA duplex oligonucleotides against K-RAS
(KRASHSS180200) were custom synthesized (Invitrogen). The sequences were
as follows: (RNA)-UGUGGUAGUUGGAGCUGGUGGCGUA and UACGCCACCAG
CUCCAACUACCACA. LNr0-8, seeded at 30% conﬂuence in a 25cm
2 culture
ﬂask overnight, were transfected with 100ng of K-RAS siRNA or random siRNA
(no. 12935-200 (Low GC), Invitrogen), using 10mg of Lipofectamine 2000
(Invitrogen) as directed by the manufacturer’s protocol. Protein lysates were
collected 72h post-transfection.
Immunocytochemistry of anti-total-Ras. Cells were seeded (60%
conﬂuence) on submerged cover slips. Cover slips were washed with PBS, then
ﬁxed and permeabilized as previously described. Permeabilized cells were blocked
(1h) in 5% normal goat serum (Vector Laboratories, Burlingame, CA, USA). Ras
was probed with anti-total-Ras diluted (1:1000) in blocking solution overnight at
41C, and then washed in PBS. Alexa-488 anti-mouse IgG (Invitrogen) was applied
(1h at RT) to the cover slips (1:500) in blocking solution. Cover slips were then
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Cell Death and Diseasewashed in PBS and mounted on top of ProLong antifade reagent with or without
DAPI (Molecular Probes).
Detection of cell viability by microscopic analysis. Cells were
cultured (2000cells per 200ml/well) in a 96 well ﬂat-bottomed microtiter plate.
Phase-contrast image analysis was conducted by a Fisher Scientiﬁc
MICROMASTER INVERTED microscope ﬁtted with a  40/1.5 NA objective.
Image were collected and prepared for publication with ADOBE PHOTOSHOP
software (Adobe Systems).
Assay of cell viability by calcein. Cells were cultured (2000cells per
200ml/well) in a 96-well ﬂat-bottomed microtiter plate (Fisher Scientiﬁc) that was
centrifuged (250g for 5min at 41C)to avoidthelossof cellsinthestainingprocess.
The media was removed (170ml) and PBS (100ml) was added to each well,
followed by the addition of Calcein-AM working solution (10ml) (EMD Chemicals,
Philadelphia, PA, USA). The plate was then incubated (371C for 1h) in a CO2
incubator. The ﬂuorescence of the samples was measured by a microtiter plate
spectrophotometer (BioTek Synergy HT plate reader, BIO-TEK) (excitation
485±10nm and emission 520±10nm). All cultures were performed in triplicate
(n¼3) and the mean was displayed as an arbitrary unit (A.U.)±S.E.
Assay of cell viability by crystal violet. Cells were cultured in a 96-well
ﬂat-bottomed microtiter plate (2000cells per 200ml/well). Subsequently, the
supernatants were discarded and the remaining viable adherent cells were stained
(5min)withcrystalviolet(0.2%)in20%ethanol.Themicrotiterplatewasthenrinsed
with water and solubilization solution (100mlo fH 2O:methanol:ethanol¼5:1:4)
was added to each well. The absorbance of each well was read at 590nm with a
microtiter plate spectrophotometer. All cultures were performed in triplicate (n¼3)
and results were expressed by mean±S.E.
Animal studies. Athymic BALB/c (nu/nu) mice (Clea Japan Inc., Tokyo,
Japan), 4 weeks of age, were subcutaneously inoculated with LNCaP cells
(5.0 10
6cells per 50ml of medium). Following the development of tumors with
diameters of 7–8mm, 24 mice were randomly assigned to four experimental
groups as follows: group 1, isotonic saline (control) (6 mice); group 2, lovastatin
(5mg/kg/day) (6 mice); group 3, mevalonate (36mmol/day) (6 mice); and group 4,
lovastatin (5mg/kg/day) and mevalonate (36mmol/day) (6 mice). 200-ml
miniosmotic pumps (ﬂow rate 0.25ml/h, 28-days pumping life) (Alzet Corp., Palo
Alto, CA, USA) were subcutaneously implanted in the intrascapular area of all mice
at Day 0. Pumps delivered either mevalonate (group 2 and group 4) or isotonic
saline (group 1 and group 3) from day 0 to day 28. The diet contain an additional
lovastatin were fed to mice of group 2 and group 4 from day 0 to day 28. The tumor
volumes were measured weekly for 4 weeks and calculated by using the following
formula: volume (a rotational ellipsoid)¼M1 M2
2 0.5236, where M1¼the
long axis and M2¼the short axis. The relative tumor volume was calculated by
assuming the rate of each tumor volume on day 0 to be 100%. Experiments in each
group were performed in six plicate and results were expressed by mean±S.D. All
theaspectsof theexperimental designandprocedurewerereviewedand approved
bythe institutionalethics andanimal welfarecommitteesof TheHyogo Universityof
Health Sciences (2009-19-1).
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